GZNL-P36 is a potent inhibitor of SARS-CoV-2 papain-like protease (PLpro) with an IC50 of 6.45 nM, demonstrating effective inhibition of SARS-CoV and its variants with EC50 values ranging from 58.2 nM to 2.66 µM. In pharmacokinetic studies conducted in CD-1 mice, GZNL-P36 achieved a peak plasma concentration (Cmax) of 549 ng/mL, a half-life (T1/2) of 1.45 hours, and a bioavailability of 74.7%. This compound exhibits notable antiviral activity in SARS-CoV-2 XXB.1 infections, positioning it as a valuable tool in therapeutic research against COVID-19.
GZNL-P36 is a potent inhibitor of SARS-CoV-2 papain-like protease (PLpro) with an IC50 of 6.45 nM, demonstrating effective inhibition of SARS-CoV and its variants with EC50 values ranging from 58.2 nM to 2.66 µM. In pharmacokinetic studies conducted in CD-1 mice, GZNL-P36 achieved a peak plasma concentration (Cmax) of 549 ng/mL, a half-life (T1/2) of 1.45 hours, and a bioavailability of 74.7%. This compound exhibits notable antiviral activity in SARS-CoV-2 XXB.1 infections, positioning it as a valuable tool in therapeutic research against COVID-19.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
